SCHEMBL5728748

SCHEMBL5728748

CCn1c(=O)n(C(c2ccccc2)[C@H](O)CO)c2ccccc21

nearest known ligand 0.75

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 16/20 0.75
SLC6A4 P31645 3/20 0.53
ALDH1A1 P00352 1/20 0.43
PKM P14618 1/20 0.43
NPSR1 Q6W5P4 1/20 0.40
PGR P06401 1/20 0.39
PABPC1 P11940 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4077345 1.00 SLC6A2 (0.75) SLC6A2SLC6A4ALDH1A1PKMNPSR1
SCHEMBL5729734 0.90 SLC6A2 (0.76) SLC6A2SLC6A4PGR
SCHEMBL4077186 0.90 SLC6A2 (0.76) SLC6A2SLC6A4PGR
SCHEMBL4091328 0.87 SLC6A2 (0.78) SLC6A2SLC6A4
SCHEMBL5728837 0.87 SLC6A2 (0.78) SLC6A2SLC6A4
SCHEMBL4081528 0.87 SLC6A2 (0.78) SLC6A2SLC6A4ALDH1A1PABPC1
SCHEMBL4086855 0.86 SLC6A2 (1.00) SLC6A2SLC6A4
SCHEMBL4086937 0.86 SLC6A2 (1.00) SLC6A2SLC6A4
SCHEMBL4086851 0.86 SLC6A2 (1.00) SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL4077101 0.85 SLC6A2 (0.98) SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1732887-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) Wyeth (US) 2006-12-20 EP disclosed
WO-2005097744-A1 1-(1H-INDOL-1-YL)-3-(4-METHYLPIPERAZIN-1-YL)-1-PHENYL PROPAN-2-OL DERIVATIVES AND RELATED COMPOUNDS AS MODULATORS OF THE NOREPINEPHRINE (NE) AND THE SEROTONINE (5-HT) ACTIVITY AND THE MONOAMINE REUPTAKE FOR THE TREATMENT OF VASOMOTOR SYMPTOMS (VMS) WYETH (US) 2005-10-20 WO disclosed